Rituximab in the Treatment of Autoimmune Haemolytic Anaemia

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 2014 Aug 21

PMID 25139610

Citations 11

Authors

Chaturaka Rodrigo

Senaka Rajapakse

Lallindra Gooneratne

Affiliations

Soon will be listed here.

Abstract

Rituximab is a B-cell depleting monoclonal antibody that is gaining popularity as an effective therapy for many autoimmune cytopenias. This article systematically evaluates its therapeutic efficacy in the treatment of different types of autoimmune haemolytic anaemia. We conclude that there is sufficient evidence to recommend it as a second line therapy for warm autoimmune haemolytic anaemia (wAIHA) either as monotherapy or combined therapy. Evidence from a single randomized controlled trial suggests that it may also be more efficacious as first line therapy in combination with steroids than steroids alone. A fewer number of studies have assessed its role in cold autoimmune haemolytic anaemia (cAIHA) and cold agglutinin disease (CAD) with success rates varying from 45-66%. In the absence of alternative definitive therapy, rituximab should be considered for patients with symptomatic CAD and significant haemolysis. Case reports of its efficacy in mixed autoimmune haemolytic anaemias are available but evidence from case series or larger cohorts are nonexistent.

Citing Articles

Rituximab as a First-line Treatment for Autoimmune Hemolytic Anemia in Multicentric Castleman's Disease.

Caceres Medina J, Gonzalez Torres L, Gamboa-Meza A, Cantu-Rodriguez O Cureus. 2024; 16(4):e59080.

PMID: 38800203 PMC: 11128291. DOI: 10.7759/cureus.59080.

Metaxalone-induced Immune Hemolytic Anemia.

Onyechi A, Ohemeng-Dapaah J, Patel R, Onyechi E, Oyenuga M, Sartaj S J Community Hosp Intern Med Perspect. 2023; 13(5):86-89.

PMID: 37868679 PMC: 10589045. DOI: 10.55729/2000-9666.1236.

A Peculiar CLL Case with Complex Chromosome 6 Rearrangements and Refinement of All Breakpoints at the Gene Level by Genomic Array: A Case Report.

Cennamo M, Sirocchi D, Giudici C, Giagnacovo M, Petracco G, Ferrario D J Clin Med. 2023; 12(12).

PMID: 37373803 PMC: 10299087. DOI: 10.3390/jcm12124110.

CAR-Based Therapy for Autoimmune Diseases: A Novel Powerful Option.

Muzes G, Sipos F Cells. 2023; 12(11).

PMID: 37296654 PMC: 10252902. DOI: 10.3390/cells12111534.

Engineering Cell Therapies for Autoimmune Diseases: From Preclinical to Clinical Proof of Concept.

Oh S, Payne A Immune Netw. 2022; 22(5):e37.

PMID: 36381961 PMC: 9634148. DOI: 10.4110/in.2022.22.e37.

References

Gupta N, Kavuru S, Patel D, Janson D, Driscoll N, Ahmed S . Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia. Leukemia. 2002; 16(10):2092-5. DOI: 10.1038/sj.leu.2402676. View

Barcellini W, Zanella A . Rituximab therapy for autoimmune haematological diseases. Eur J Intern Med. 2011; 22(3):220-9. DOI: 10.1016/j.ejim.2010.12.016. View

Berentsen S, Ulvestad E, Gjertsen B, Hjorth-Hansen H, Langholm R, Knutsen H . Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood. 2004; 103(8):2925-8. DOI: 10.1182/blood-2003-10-3597. View

Mori A, Tamaru J, Sumi H, Kondo H . Beneficial effects of rituximab on primary cold agglutinin disease refractory to conventional therapy. Eur J Haematol. 2002; 68(4):243-6. DOI: 10.1034/j.1600-0609.2002.01667.x. View

Carson K, Evens A, Richey E, Habermann T, Focosi D, Seymour J . Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood. 2009; 113(20):4834-40. PMC: 2686134. DOI: 10.1182/blood-2008-10-186999. View

Gomez-Almaguer D, Solano-Genesta M, Tarin-Arzaga L, Herrera-Garza J, Cantu-Rodriguez O, Gutierrez-Aguirre C . Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias. Blood. 2010; 116(23):4783-5. DOI: 10.1182/blood-2010-06-291831. View

Birgens H, Frederiksen H, Hasselbalch H, Rasmussen I, Nielsen O, Kjeldsen L . A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. Br J Haematol. 2013; 163(3):393-9. DOI: 10.1111/bjh.12541. View

Ahrens N, Kingreen D, Seltsam A, Salama A . Treatment of refractory autoimmune haemolytic anaemia with anti-CD20 (rituximab). Br J Haematol. 2001; 114(1):244-5. DOI: 10.1046/j.1365-2141.2001.02873-4.x. View

Schollkopf C, Kjeldsen L, Bjerrum O, Mourits-Andersen H, Nielsen J, Christensen B . Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients. Leuk Lymphoma. 2005; 47(2):253-60. DOI: 10.1080/10428190500286481. View

10.

Koppel A, Lim S, Osby M, Garratty G, Goldfinger D . Rituximab as successful therapy in a patient with refractory paroxysmal cold hemoglobinuria. Transfusion. 2007; 47(10):1902-4. DOI: 10.1111/j.1537-2995.2007.01414.x. View

11.

Barcellini W, Zaja F, Zaninoni A, Imperiali F, Battista M, Di Bona E . Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studies. Blood. 2012; 119(16):3691-7. DOI: 10.1182/blood-2011-06-363556. View

12.

Petz L . Cold antibody autoimmune hemolytic anemias. Blood Rev. 2007; 22(1):1-15. DOI: 10.1016/j.blre.2007.08.002. View

13.

Gupta S, Szerszen A, Nakhl F, Varma S, Gottesman A, Forte F . Severe refractory autoimmune hemolytic anemia with both warm and cold autoantibodies that responded completely to a single cycle of rituximab: a case report. J Med Case Rep. 2011; 5:156. PMC: 3096571. DOI: 10.1186/1752-1947-5-156. View

14.

Quinn J, Gilligan O, Horgan M . Evan's syndrome complicating multicentric Castleman's disease -- dramatic response to rituximab. Eur J Haematol. 2004; 73(5):384-5. DOI: 10.1111/j.1600-0609.2004.00302.x. View

15.

Simms-Waldrip T, Ikeda A, Goldfinger D, Moore T, Yuan S . Dramatic response to rituximab in a child with severe cold autoimmune hemolytic anemia arising after allogeneic hematopoietic SCT. Bone Marrow Transplant. 2009; 45(1):201-2. DOI: 10.1038/bmt.2009.108. View

16.

Sekkach Y, Hammi S, Elqatni M, Fatihi J, Elomri N, Mekouar F . [Efficacity of rituximab in hemolytic anemia with cold autoantibodies case]. Ann Pharm Fr. 2011; 69(4):205-8. DOI: 10.1016/j.pharma.2011.06.002. View

17.

Bussone G, Ribeiro E, Dechartres A, Viallard J, Bonnotte B, Fain O . Efficacy and safety of rituximab in adults' warm antibody autoimmune haemolytic anemia: retrospective analysis of 27 cases. Am J Hematol. 2009; 84(3):153-7. DOI: 10.1002/ajh.21341. View

18.

Penalver F, Alvarez-Larran A, Diez-Martin J, Gallur L, Jarque I, Caballero D . Rituximab is an effective and safe therapeutic alternative in adults with refractory and severe autoimmune hemolytic anemia. Ann Hematol. 2010; 89(11):1073-80. DOI: 10.1007/s00277-010-0997-y. View

19.

DArena G, Laurenti L, Capalbo S, Maria DArco A, De Filippi R, Marcacci G . Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia. Am J Hematol. 2006; 81(8):598-602. DOI: 10.1002/ajh.20665. View

20.

Motto D, Williams J, Boxer L . Rituximab for refractory childhood autoimmune hemolytic anemia. Isr Med Assoc J. 2002; 4(11):1006-8. View